Dr Reddy's Laboratories (DRREDDY IS) says Novo Nordisk's (NOVOB DC) Wegovy copycat will be priced competitively with 50-60% discounts feasible, according to reports

The announcement from Dr Reddy's regarding Novo Nordisk's Wegovy copycat suggests a significant price competition in the market for weight loss drugs.

Newsquawk StaffPublished On the live feed at 4 more headlines followed before this page went public
Newsquawk headlinesUTC

Newsquawk Daily Economic Releases - 18th February 2026

US is to sell USD 69bln of 17-week bills on February 18th, and USD 95bln of 8-week bills and USD 105bln of 4-week bills on February 19th; all to settle on February 24th

Dr Reddy's Laboratories (DRREDDY IS) says Novo Nordisk's (NOVOB DC) Wegovy copycat will be priced competitively with 50-60% discounts feasible, according to reports

Tripadvisor (TRIP) responds to Starboard; says it regularly engages with shareholders; has held talks with Starboard

General Motors (GM) CFO says the tariff environment is getting more stable, adding that he anticipates 2026 to be the most stable year in a while

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

A 50-60% discount could indicate a strong push to capture market share, potentially impacting margins and pricing strategies for peers in the pharmaceutical sector. Investors should watch for potential ripple effects on the competitive landscape and the valuations of companies with similar offerings.

Related headlines

The whole workspace, free to try.

Try it free